This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
SNN Stock Rises on the Completion of First Case With CATALYSTEM System
by Zacks Equity Research
Smith & Nephew announces the completion of the first case using the CATALYSTEM Primary Hip System.
DGX Stock to Benefit From New Partnership With Sentara Health Plans
by Zacks Equity Research
Quest Diagnostics extends services in Virginia and Florida via a partnership with Sentara Health Plans.
Here's Why You Should Retain McKesson Stock in Your Portfolio Now
by Zacks Equity Research
MCK's strategic collaborations and strength in Biologics raise optimism about the stock.
GEHC Stock Rises as FDA Clears MIM Software's Centiloid Tool
by Zacks Equity Research
GE Healthcare's MIM Software announces the receipt of FDA clearance for its Centiloid scaling tool to perform PET-based amyloid imaging.
CAH Stock May Gain Following the Distribution Agreement With Telix
by Zacks Equity Research
Cardinal Health and Telix announce an agreement selecting the former as a commercial radiopharmaceutical distributor to supply finished unit doses of Telix's Zircaix.
Here's Why You Should Retain Accuray Stock in Your Portfolio Now
by Zacks Equity Research
ARAY's solid product demand and revenue growth raise optimism about the stock.
NSPR Stock Declines Despite PMA Application Submission for CGuard
by Zacks Equity Research
InspireMD announces the submission of the PMA application to the FDA for marketing approval of the CGuard Prime EPS.
Tactile Medical's Shares Rise After PDAC Approval for Nimbl
by Zacks Equity Research
TCMD's Nimbl pneumatic compression system gets CMS PDAC approval and is set to be launched in the United States soon, following FDA clearance for treating lymphedema.
DGX Stock Likely to Gain From Allina Health's Select Lab Assets Buyout
by Zacks Equity Research
With the completion of the acquisition, Allina Health's clinic physicians will now have access to Quest Diagnostics' laboratory services.
CVRX Stock Gains on Unveiling of Barostim's Positive Study Data
by Zacks Equity Research
CVRx announces the publication of positive study data for its Barostim therapy.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Masimo Stock Likely to Rise With Qualcomm Wear OS Partnership
by Zacks Equity Research
MASI Collaborates with Qualcomm to develop a reference platform for Wear OS smartwatches, combining biosensing tech and Snapdragon chips to enhance performance and connectivity.
Merit Medical Gains 26.4% Year to Date: What's Driving the Stock?
by Zacks Equity Research
MMSI's shares gain on the back of strength in its Cardiovascular segment and a robust product portfolio.
SNN Stock Declines Despite the Launch of Its Patient-Matched Guides
by Zacks Equity Research
Smith & Nephew announces the launch of its TOTAL ANKLE Patient-Matched Guides to plan and perform total ankle replacement procedures.
iRhythm's Zio ECG System Gets Approval in Japan, Stock Falls
by Zacks Equity Research
IRTC's Zio ECG monitoring system gets approval in Japan, marking a significant step in revolutionizing arrhythmia diagnostics with AI-powered technology.
Avanos Medical Stock May Gain From Brand Partnership With NFL
by Zacks Equity Research
AVNS' GAME READY announces a paid partnership with NFL defensive end and San Francisco 49ers star, Nick Bosa.
SYK Stocks Gains Following Expansion of Foot & Ankle Portfolio
by Zacks Equity Research
Stryker unveils two new products, enhancing precision and outcomes in foot and ankle surgeries.
Factors Driving Veeva Stock More Than 20% in Three Months
by Zacks Equity Research
Robust quarterly results on the back of new partnerships and rising subscription revenues are driving VEEV's shares.
Why Brookdale May Not Be a Safe Bet Despite 34-Month Occupancy Growth
by Zacks Equity Research
Rising operating costs due to inflationary challenges in the senior living industry and higher estimated insurance expenses are likely to keep BKD's margins under pressure.
PacBio Stock Drops After Singapore Collaboration for HiFi Sequencing
by Zacks Equity Research
PACB's HiFi sequencing powers the HiFi Consortium's global effort to enhance the diagnosis and treatment of subfertility and recurrent pregnancy loss.
Labcorp Stock Gains From Market Expansion Efforts Amid Macro Woes
by Zacks Equity Research
LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.
Solventum Shares May Gain on the Launch of Its New V.A.C Therapy
by Zacks Equity Research
SOLV announces the launch of its V.A.C. Peel and Place Dressing for providing efficient and effective care in case of negative pressure wound therapy.
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
PacBio's Stock Up on Munster Deal for Male Infertility Research
by Zacks Equity Research
PACB collaborates with the University Hospital of Munster, using Revio HiFi sequencing to advance research on male infertility and rare diseases in Germany and globally.
Paragon 28 Stock Gains From the Latest Launch of Its Right-Angle Drill
by Zacks Equity Research
FNA launched the Right-Angle Drill to enhance the APEX 3D Total Ankle Replacement System. The drill is designed to improve tibia preparation.